Advertisement
Advertisement
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
3.24
USDSponsored
-0.17
-4.99%
Sep 15, 15:56 UTC -4
Closed
After-Market
3.24
0.00
0.00%
RXRX Earnings Reports
Positive Surprise Ratio
RXRX beat 13 of 21 last estimates.
62%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$14.48M
/-$0.23
Implied change from Q2 26 (Revenue/ EPS)
+88.76%
/-8.00%
Implied change from Q3 25 (Revenue/ EPS)
+179.77%
/-36.11%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Aug 05, 2026, RXRX reported earnings of -0.25 USD per share (EPS) for Q2 26, missing the estimate of -0.23 USD, resulting in a -4.73% surprise. Revenue reached 7.67 million, compared to an expected 12.19 million, with a -37.06% difference. The market reacted with a -4.23% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 14.48 million USD, implying an decrease of -8.00% EPS, and increase of 88.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.25, missing estimates by -4.73%, and revenue of $7.67M, -37.06% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved down -4.23%, changed from $3.31 before the earnings release to $3.17 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.23 and revenue of $14.48M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.